Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1143 | TNBC | Basal A | Nilotinib | ABL | nRTK | 8 | uM | 12112.145 | 0.8617 | 0.8511 | 1.9247 | |
| HCC1143 | TNBC | Basal A | Nilotinib | ABL | nRTK | 40 | uM | 12112.145 | 1.0724 | 1.0740 | 1.9247 | |
| HCC1143 | TNBC | Basal A | Nilotinib | ABL | nRTK | 200 | uM | 12112.145 | 0.9387 | 0.9353 | 1.9247 | |
| HCC1187 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.000512 | uM | 10753.145 | 0.9693 | 0.9594 | 1.5180 | |
| HCC1187 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.00256 | uM | 10753.145 | 0.8838 | 0.8438 | 1.5180 | |
| HCC1187 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.0128 | uM | 10753.145 | 0.9648 | 0.9533 | 1.5180 | |
| HCC1187 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.064 | uM | 10753.145 | 0.8802 | 0.8387 | 1.5180 | |
| HCC1187 | TNBC | Basal A | Nilotinib | ABL | nRTK | 0.32 | uM | 10753.145 | 0.9754 | 0.9675 | 1.5180 | |
| HCC1187 | TNBC | Basal A | Nilotinib | ABL | nRTK | 1.6 | uM | 10753.145 | 0.8675 | 0.8213 | 1.5180 | |
| HCC1187 | TNBC | Basal A | Nilotinib | ABL | nRTK | 8 | uM | 10753.145 | 0.7069 | 0.5914 | 1.5180 | |
| HCC1187 | TNBC | Basal A | Nilotinib | ABL | nRTK | 40 | uM | 10753.145 | 0.8048 | 0.7334 | 1.5180 | |
| HCC1187 | TNBC | Basal A | Nilotinib | ABL | nRTK | 200 | uM | 10753.145 | 0.6553 | 0.5140 | 1.5180 | |
| HCC1395 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.000512 | uM | 12000.145 | 0.9852 | 0.9517 | 0.6084 | |
| HCC1395 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.00256 | uM | 12000.145 | 0.9370 | 0.7972 | 0.6084 | |
| HCC1395 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.0128 | uM | 12000.145 | 0.9618 | 0.8761 | 0.6084 | |
| HCC1395 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.064 | uM | 12000.145 | 0.9621 | 0.8769 | 0.6084 | |
| HCC1395 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.32 | uM | 12000.145 | 1.0171 | 1.0567 | 0.6084 | |
| HCC1395 | TNBC | Basal B | Nilotinib | ABL | nRTK | 1.6 | uM | 12000.145 | 0.9730 | 0.9120 | 0.6084 | |
| HCC1395 | TNBC | Basal B | Nilotinib | ABL | nRTK | 8 | uM | 12000.145 | 0.9835 | 0.9462 | 0.6084 | |
| HCC1395 | TNBC | Basal B | Nilotinib | ABL | nRTK | 40 | uM | 12000.145 | 1.0447 | 1.1489 | 0.6084 | |
| HCC1395 | TNBC | Basal B | Nilotinib | ABL | nRTK | 200 | uM | 12000.145 | 1.0220 | 1.0727 | 0.6084 | |
| HCC1395 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.000512 | uM | 12084.145 | 0.9987 | 0.9978 | 1.1692 | |
| HCC1395 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.00256 | uM | 12084.145 | 0.9962 | 0.9935 | 1.1692 | |
| HCC1395 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.0128 | uM | 12084.145 | 1.0246 | 1.0420 | 1.1692 | |
| HCC1395 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.064 | uM | 12084.145 | 0.9641 | 0.9383 | 1.1692 |